Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it

梅奥诊所推出远程诊断平台,组建2家新公司支持

2021-04-15 03:00:10 Healthcare IT News

本文共1780个字,阅读需5分钟

Mayo Clinic on Wednesday announced the launch of a new platform that's designed to deliver advanced, AI-powered clinical decision support through remote monitoring. It helps providers stay connected and deliver more continuous care to device-connected patients. WHY IT MATTERS The health system's new Remote Diagnostics and Management Platform was created to deliver what it calls "event-driven medicine," connecting patient data with machine learning algorithms within existing clinical workflows and enabling care in the "right context, at the right time." "The dramatically increased use of remote patient telemetry devices, coupled with the rapidly accelerating development of AI and machine learning algorithms, has the potential to revolutionize diagnostic medicine," said Mayo Clinic Platform president Dr. John Halamka in a statement. "With RDMP, clinicians will have access to best-in-class algorithms and care protocols and will be able to serve more patients effectively in remote care settings," he added. "The platform will also enable patients to take more control of their health and make better decisions based on insights delivered directly to them." To help the new platform capitalize on its potential, Mayo Clinic worked with vendor partners to launch two new spinoff companies, each focused on a specific aspect of that AI-powered connected health. Anumana, created in collaboration with biomedical-data company nference, is focused on commercialization of AI-enabled algorithms and bringing digital sensor diagnostics to market. Its first goal is to improve early detection and treatment of heart disease by designing new neural-network algorithms based on troves of heart health data in Mayo's Clinical Data Analytics Platform, including raw ECG signals. Lucem Health, meanwhile, is designed to "collect, orchestrate and curate data from any device," according to Mayo Clinic. Launched with doctor-focused developer startup Commure, Lucem will provide the overall platform for connecting remote-telemetry devices with the algorithms developed by Anumana and Mayo, and will be responsible for integrating those AI-powered diagnostic insights into clinical workflows. Anumana completed $25.7 million in Series A financing, led by founders nference and Mayo Clinic, along with Matrix Capital Management, Matrix Partners and NTTVC, as part of this initiative. Lucem Health completed $6 million in Series A, led by Mayo and Commure. "When technology and policy and culture align, you see radical change and innovation," said Halamka during a teleconference announcing the RDMP launch. "Think for a moment what we've seen over this last year of COVID-19. We see that all of us are carrying these super-computing devices. Many of us have wearable devices. In fact, our homes may be smart and have sensors. "So here's the interesting quandary," he said. "If you, as a primary care provider or specialist, want to work with a patient, if you were the payer or pharma or government and you want to ensure the health and wellbeing of a population, how do you take all this new data that is coming from the devices we have, and wear, and are in our homes around us, and turn it into wisdom? How do you respond to events rapidly? How do you filter the signal from the noise? "What's happening in 2021 is we are seeing the emergence of sophisticated AI algorithms that can, in combination with novel data sources, result in breakthroughs in disease detection and wellness," he added. "But that will require an assembly of technology, policy and patient engagement, combined with cultural change in order to make it happen." THE LARGER TREND "Undiagnosed heart disease affects millions of Americans, and people across the globe," said Dr. Paul Friedman, chair of the Department of Cardiovascular Medicine at Mayo Clinic. "For many conditions, such as a weak or thickened heart pump, or silent arrhythmias, effective evidence-based treatments exist that can prevent heart failure, stroke or death. The key is to detect the disease before symptoms develop to prevent these events from happening. The addition of AI to the ECG, a ubiquitous and inexpensive point-of-care test that is already integrated into medical workflows, makes this approach good for patients, convenient for clinicians and massively scalable." ON THE RECORD "ECGs have been read and notated manually by physicians for more than a century," said Murali Aravamudan, cofounder and CEO of nference and CEO of Anumana, in a statement. "Our augmented intelligence technology, in the hands of scientific and clinical experts, will enable a comprehensive translation of the language of the heart. We think of it as the Rosetta Stone for cardiac medicine." "Lucem Health exists to help diagnostic medicine innovations see the light of day," said Sean Cassidy, founding CEO of Lucem Health. "We are excited to work with partners like Mayo Clinic and Anumana that are reimagining how we detect and treat diseases." Twitter: @MikeMiliardHITN Email the writer: mike.miliard@himssmedia.comHealthcare IT News is a HIMSS publication.
梅奥诊所周三宣布推出一个新平台,旨在通过远程监控提供先进的、以人工智能为动力的临床决策支持。它帮助提供商保持连接,并为连接设备的患者提供更多的持续护理。 为什么重要 卫生系统新的远程诊断和管理平台的创建是为了提供它所说的“事件驱动医学”,将患者数据与现有临床工作流程中的机器学习算法连接起来,并在“正确的环境、正确的时间”中实现护理。 梅奥诊所平台总裁约翰·哈拉姆卡博士在一份声明中说:“远程患者遥测设备的使用急剧增加,加上AI和机器学习算法的快速加速发展,有可能使诊断医学发生革命性变化。” 他补充说:“有了RDMP,临床医生将能够使用一流的算法和护理协议,并能够在远程护理环境中有效地为更多的病人服务。”“该平台还将使患者能够更好地控制自己的健康,并根据直接传递给他们的见解做出更好的决定。” 为了帮助新平台充分利用其潜力,梅奥诊所与供应商合作伙伴合作,成立了两家新的分拆公司,各自专注于人工智能驱动的互联健康的一个特定方面。 Anumana是与生物医学数据公司nference合作创建的,专注于人工智能算法的商业化,并将数字传感器诊断推向市场。它的第一个目标是通过基于梅奥临床数据分析平台中包括原始心电信号在内的大量心脏健康数据设计新的神经网络算法,改善心脏病的早期检测和治疗。 同时,根据梅奥诊所的说法,Lucem Health设计用于“从任何设备收集、编排和管理数据”。Lucem与专注于医生开发的初创公司Commure合作推出,将提供连接远程遥测设备与Anumana和Mayo开发的算法的整体平台,并将负责将这些人工智能驱动的诊断洞察力整合到临床工作流程中。 Anumana完成了2570万美元的A系列融资,由创始人nference和Mayo Clinic,以及Matrix Capital Management、Matrix Partners和NTTVC牵头,作为这一举措的一部分。Lucem Health在A系列中完成600万美元,由梅奥和康莫尔领衔。 Halamka在宣布RDMP启动的电话会议上说:“当技术、政策和文化协调一致时,你会看到彻底的变化和创新。”“想一想我们在过去一年的新冠肺炎疫情中看到了什么。我们看到我们所有人都携带着这些超级计算设备。我们中的许多人都有可穿戴设备。事实上,我们的家可能是智能的,有传感器。” “这是一个有趣的困惑,”他说。“如果你作为一个初级保健提供者或专家,想要和病人一起工作,如果你是付款人、医药公司或政府,你想要确保一个人口的健康和福祉,你如何把所有这些来自我们拥有的、佩戴的以及我们身边的设备的新数据转化为智慧?你如何对事件做出快速反应?你如何从噪声中过滤信号? 他补充说:“2021年的情况是,我们将看到复杂的人工智能算法的出现,这些算法与新的数据源相结合,将在疾病检测和健康方面带来突破。”“但这需要技术、政策和耐心的参与,再加上文化变革,才能实现这一目标。” 更大的趋势 梅奥诊所心血管内科主任保罗·弗里德曼博士说:“未经诊断的心脏病影响着数百万美国人和全世界的人。” “对于许多情况,如心脏泵弱或增厚,或无症状心律失常,存在有效的循证治疗方法,可以防止心力衰竭、中风或死亡。关键是在症状出现之前发现疾病,以防止这些事件的发生。在ECG中添加人工智能,这是一种普遍存在且价格低廉的护理点测试,已经集成到医疗工作流程中,使这种方法对患者有益,对临床医生方便,并具有大规模可扩展性。” 记录在案 nference公司联合创始人兼首席执行官兼Anumana公司首席执行官Murali Aravamudan在一份声明中说:“一个多世纪以来,心电图一直由医生手工读取和标注。”“我们的增强智能技术,在科学和临床专家的手中,将使心脏语言的全面翻译。我们认为它是心脏医学的罗塞塔石。” Lucem Health公司的创始首席执行官肖恩·卡西迪说:“Lucem Health公司的存在是为了帮助诊断医学创新见诸报端。“我们很高兴能与梅奥诊所和Anumana这样的合作伙伴合作,他们正在重新想象我们如何检测和治疗疾病。” 推特:@MikeMiliardhitn 发电子邮件给作者:mike.miliard@himssmedia.comhealthcare IT News是HIMSS的出版物。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文